SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

NCT03816553 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Cervical Carcinoma
Metastatic Cervical Cancer

Interventions

DRUG: SHR-1210
DRUG: Apatinib

Sponsor

Sun Yat-sen University